Jazz Pharmaceuticals plc (JAZZ)
Market Cap | 8.17B |
Revenue (ttm) | 3.76B |
Net Income (ttm) | -86.51M |
Shares Out | 63.13M |
EPS (ttm) | -1.59 |
PE Ratio | n/a |
Forward PE | 6.41 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 473,313 |
Open | 131.54 |
Previous Close | 131.03 |
Day's Range | 129.25 - 131.80 |
52-Week Range | 120.64 - 160.96 |
Beta | 0.71 |
Analysts | Strong Buy |
Price Target | 203.86 (+57.49%) |
Earnings Date | Nov 8, 2023 |
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) i... [Read more]
Financial Performance
In 2022, JAZZ's revenue was $3.66 billion, an increase of 18.26% compared to the previous year's $3.09 billion. Losses were -$224.06 million, -32.03% less than in 2021.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price forecast is $203.86, which is an increase of 57.49% from the latest price.
News

Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
SAN DIEGO--(BUSINESS WIRE)--Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze.

Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
DUBLIN , Sept. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted marketing authorization for Enrylaze® (JZP458; a recombina...

Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences
DUBLIN , Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.

Jazz Pharmaceuticals Announces Key Update to Leadership Team
Renée Galá promoted to President and Chief Operating Officer DUBLIN , Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, h...

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023
Six presentations demonstrated Jazz's commitment to providing solutions for people living with difficult-to-treat sleep disorders Review of multiple clinical trials provided a comprehensive analysis ...

10 growth stocks that are trading at bargain prices, including Delta and Cheniere Energy
Some investors place themselves in either the growth camp — focusing on the most rapidly growing companies, no matter how high their stock prices may be — or the value camp, going with slow growers th...

Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference
DUBLIN , Aug. 24, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Citi Annual BioPharma Conference in Boston. Company management w...

Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
– Strong execution delivered second quarter 2023 total revenues of $957 million –– Commercial excellence drove continued adoption of low-sodium Xywav®; net product sales increased 39% year-over-year –...

Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023
DUBLIN , July 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 second quarter financial results on Wednesday, August 9, 2023, after the clo...

Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
DUBLIN , July 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted ...

NASDAQ Stocks Hitting New 52-Week Lows: 4 Stocks To Watch
While a very few are just now coming off of all-time highs (Nvidia, among others), some are recently all the way down to new 52-week lows.

Top Pharmaceutical And Ancillary Cannabis Stocks For June 2023
Do you intend to invest in marijuana stocks in 2023? Over the last decade, the cannabis industry has grown incredibly, transitioning from a taboo subject to a respectable and wealthy corporate sector...

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of...

Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia DUBLIN , May 31, 2023 /PRNewswire/ -- ...

Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference
DUBLIN , May 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference. Company manageme...

Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT DUBLIN , May 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will h...

Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance
Focus on commercial execution drove 1Q23 total revenues of $892.8 million Continued adoption of Xywav ® ; net product sales increased 49% 1Q23 compared to 1Q22 Confident in blockbuster potential of Ep...

Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
DUBLIN , May 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 RBC Capital Markets Global Healthcare Conference. Company man...

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor potenti...

Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023
DUBLIN , April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023, after the close...

Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders Three oral presentations share meaningful data ...

Top Pot Stocks For Long Term Investing? 3 To Watch In April
Are Pot Stocks On Your List For April? The post Top Pot Stocks For Long Term Investing? 3 To Watch In April appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Indus...

Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health
Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations Research shows that sleep disorders ar...

Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
DUBLIN, March 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association fo...